Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04536688 · ClinicalTrials.gov registry record · Phase 1
A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease
A Phase 1 study, sponsored by Regulus Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT04536688: Completed Phase 1 study, sponsored by Regulus Therapeutics.
NCT04536688 is a Phase 1 study that has completed, run by Regulus Therapeutics. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04536688, a Phase 1 study, has completed, sponsored by Regulus Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
Primary Objective • To assess the dose response relationship between RGLS4326 and ADPKD biomarkers Secondary Objectives * To characterize the pharmacokinetic (PK) properties of RGLS4326 in plasma and urine * To assess the safety and tolerability of RGLS4326
Primary Outcome
Changes in polycystin-1 (PC-1) and polycystin-2 (PC-2) protein levels in urinary exosomes from baseline to Day 44
Interventions
- DRUG RGLS4326
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2021-11-12 |
| Phase | Phase 1 |
What the finished NCT04536688 record still lists
NCT04536688 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 1 intervention - of which RGLS4326 is the first listed.
NCT04536688 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04536688 about?
NCT04536688 is a clinical study titled "A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease". Primary Objective • To assess the dose response relationship between RGLS4326 and ADPKD biomarkers Secondary Objectives * To characterize the pharmacokinetic (PK) properties of RGLS4326 in plasma and urine * To assess the safety and tolerability of RGLS4326
What is the current status of trial NCT04536688?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2020-10-13. Estimated completion is 2021-11-12.
What interventions are being tested in trial NCT04536688?
The interventions under investigation include: RGLS4326 (DRUG).
Who is sponsoring clinical trial NCT04536688?
This trial is sponsored by Regulus Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04536688's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI